ClassID:

21159

A61K2039/505 - page 7 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies comprising antibodies

Recent Application in this class:
#1801
20250060370
2025-02-20

METHOD OF TREATING AN AUTOIMMUNE DISEASE BY ADMINISTERING AN ANTI-HUMAN BAFF ANTIBODY

#1802
20250059301
2025-02-20

Fusion Protein Construct

#1803
20250059300
2025-02-20

METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODY

#1804
20250059299
2025-02-20

Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation

#1805
20250059297
2025-02-20

ANTI-HER2/TROP2 ANTIBODIES AND USES THEREOF

#1806
20250059295
2025-02-20

STEAP2 DIRECTED T-CELL ENGAGERS AND COMPOSITIONS THEREOF

#1807
20250059293
2025-02-20

CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY

#1808
20250059291
2025-02-20

CD27 AGONISTS

#1809
20250059290
2025-02-20

ANTI-OX40 ANTAGONISTIC ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES

#1810
20250059289
2025-02-20

DOSING AND TREATMENT OF IMMUNE-MEDIATED DISEASES AND BIOMARKERS ASSOCIATED WITH IMMUNE-MEDIATED DISEASES

#1811
20250059287
2025-02-20

COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASE

#1812
20250059283
2025-02-20

CHIMERIC ANTIGEN RECEPTORS TARGETING FC RECEPTOR-LIKE 5 AND USES THEREOF

#1813
20250059282
2025-02-20

DUAL SPECIFICITY ANTIBODIES TO HUMAN PD-L1 AND PD-L2 AND METHODS OF USE THEREFOR

#1814
20250059277
2025-02-20

ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS

#1815
20250059275
2025-02-20

TIGIT ANTIBODIES AND USES THEREOF

#1816
20250059273
2025-02-20

HUMANIZED NON-OPIOID COMPOSITION AND THERAPIES FOR PAIN MANAGEMENT

#1817
20250059270
2025-02-20

IL-6 ANTIBODIES

#1818
20250059268
2025-02-20

COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES

#1819
20250059266
2025-02-20

ANTIBODIES FOR TREATING ALPHA-SYNUCLEINOPATHIES

#1820
20250059263
2025-02-20

ERYTHROCYTE-BINDING THERAPEUTICS

#1821
20250059261
2025-02-20

MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE

#1822
20250059260
2025-02-20

METHODS FOR DETECTING OR TREATING INFLUENZA INFECTIONS

#1823
20250059256
2025-02-20

HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF

#1824
20250059249
2025-02-20

INTERLEUKIN-2 AGENTS AND USES THEREOF

#1825
20250059242
2025-02-20

METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS

#1826
20250058000
2025-02-20

Treatment of Proliferative Disorders Using Antibodies to PSMA

#1827
20250057847
2025-02-20

PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER

#1828
20250052759
2025-02-13

BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS

#1829
20250051477
2025-02-13

ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS

#1830
20250051474
2025-02-13

ANTI-CD97 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES

#1831
20250051473
2025-02-13

ANTI-CD38 BINDING MOLECULES AND USES THEREOF

#1832
20250051471
2025-02-13

Anti-Abcb1 Antibodies

#1833
20250051468
2025-02-13

ANTIBODY AGAINST OX40 AND MEDICAL USE THEREOF

#1834
20250051467
2025-02-13

FAP/CD40 BINDING MOLECULE AND MEDICINAL USE THEREOF

#1835
20250051465
2025-02-13

ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR

#1836
20250051464
2025-02-13

EPHA2 ANTIBODIES

#1837
20250051462
2025-02-13

ANTIBODIES AGAINST G-CSFR AND USES THEREOF

#1838
20250051461
2025-02-13

Methods for the treatment of thyroid eye disease

#1839
20250051460
2025-02-13

BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES

#1840
20250051459
2025-02-13

WNT-SURROGATE AGENTS AND METHODS FOR LACRIMAL GLAND REGENERATION

#1841
20250051457
2025-02-13

ASGR INHIBITORS

#1842
20250051455
2025-02-13

MULTISPECIFIC ANTIBODIES AND USE THEREOF

#1843
20250051453
2025-02-13

METHODS FOR TREATING BULLOUS PEMPHIGOID USING FCRN ANTAGONISTS

#1844
20250051451
2025-02-13

ANTI-B7-H3 MONOCLONAL ANTIBODY AND USE THEREOF IN CELL THERAPY

#1845
20250051450
2025-02-13

USE OF ANTI-PD-L1/CD47 BISPECIFIC ANTIBODY IN TREATMENT OF DISEASES

#1846
20250051449
2025-02-13

Anti-CD112R Compositions and Methods

#1847
20250051448
2025-02-13

LAG-3 COMBINATION THERAPY FOR THE TREATMENT OF CANCER

#1848
20250051446
2025-02-13

Anti-CD28 Humanized Antibodies Formulated for Administration to Humans

#1849
20250051444
2025-02-13

MULTI-SPECIFIC T CELL ENGAGERS COMPRISING LRRC15 ANTIGEN-BINDING DOMAIN

#1850
20250051440
2025-02-13

DEPLETION OF NK CELLS FOR THE TREATMENT OF ADVERSE POST-ISCHEMIC CARDIAC REMODELING

#1851
20250051436
2025-02-13

Arthritis Treatment

#1852
20250051434
2025-02-13

MONOVALENT INTERLEUKIN 12 (IL-12) HETERODIMERIC FC PROTEINS

#1853
20250051432
2025-02-13

METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY

#1854
20250051431
2025-02-13

Antibody Variants

#1855
20250051430
2025-02-13

NEUTRALIZATION OF ACYL-COA BINDING PROTEIN CONFERS AUTOPHAGY-DEPENDENT ORGAN PROTECTION

#1856
20250051429
2025-02-13

ANTI-A-BETA PROTEIN ANTIBODIES, METHODS AND USES THEREOF

#1857
20250051428
2025-02-13

ANTIBODIES TO AMYLOID BETA

#1858
20250051425
2025-02-13

ANTIBODIES HAVING PAN-ANTIVIRAL ACTIVITY AND METHODS THEREOF

#1859
20250049890
2025-02-13

FUSION PROTEINS COMPOSED OF AN ANTIBODY AND A MUTEIN

#1860
20250049828
2025-02-13

PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS AND USE

#1861
20250049804
2025-02-13

FERROCHELATASE INHIBITORS AND METHODS OF USE

#1862
20250049757
2025-02-13

COMBINATORY THERAPY FOR CANCER USING BIPHENYL COMPOUND AND IMMUNE CHECKPOINT MOLECULE REGULATOR

#1863
20250043026
2025-02-06

FC POLYPEPTIDE HAVING ALTERED GLYCOSYLATION MODIFICATION

#1864
20250043022
2025-02-06

ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO PSMA AND CD3, AND PHARMACEUTICAL USE THEREOF

#1865
20250043020
2025-02-06

IMMUNOREACTIVE MOLECULES AND USES THEREOF

#1866
20250043019
2025-02-06

TRISPECIFIC ANTIBODY TARGETING CD79b, CD20, AND CD3

#1867
20250043018
2025-02-06

ANTIBODY VARIANTS AND USES THEREOF

#1868
20250043017
2025-02-06

BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF

#1869
20250043016
2025-02-06

TNFR2 BINDING MOLECULE AND USE THEREOF

#1870
20250043015
2025-02-06

ANTI-TNFR2 SINGLE DOMAIN ANTIBODY, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

#1871
20250043014
2025-02-06

ANTIBODY MOLECULES TO APRIL AND USES THEREOF

#1872
20250043005
2025-02-06

ANTIBODY-CYTOKINE FUSION PROTEINS AND APPLICATIONS THEREOF

#1873
20250042991
2025-02-06

LEPTIN ANTIBODIES AND METHOD OF REDUCING LEPTIN

#1874
20250042990
2025-02-06

ANTI-IL-1-BETA ANTIBODIES

#1875
20250042989
2025-02-06

Gout flare prevention methods using IL-1BETA blockers

#1876
20250042986
2025-02-06

STEM CELL FACTOR INHIBITOR

#1877
20250042985
2025-02-06

INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN FOR USE IN TREATING POLYANGIITIS, HYPEREOSINOPHILIC SYNDROME, CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP), OR CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP)

#1878
20250042983
2025-02-06

ANTI-LCN-2 ANTIBODIES AS A TREATMENT FOR EYE DISORDERS

#1879
20250042982
2025-02-06

ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF

#1880
20250042979
2025-02-06

HIGH DOSE TREATMENTS FOR ALZHEIMER'S DISEASE

#1881
20250042978
2025-02-06

VHH BASED BINDING ANTIBODIES FOR ANTHRAX AND BOTULINUM TOXINS AND METHODS OF MAKING AND USING THEREFOR

#1882
20250042977
2025-02-06

C-BASED SINGLE DOMAIN ANTIBODY FOR NEUTRALIZING RESPIRATORY SYNCYTIAL VIRUS AND APPLICATION THEREOF

#1883
20250042975
2025-02-06

NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO

#1884
20250042971
2025-02-06

LAIR-2 Compositions and Methods

#1885
20250041424
2025-02-06

METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY

#1886
20250041410
2025-02-06

Formulations Comprising a SADA Complex

#1887
20250041355
2025-02-06

Pharmaceutical Composition Comprising Salmonella Strain and Immune Checkpoint Inhibitor as Active Ingredient for Prevention or Treatment of Cancer

#1888
20250041313
2025-02-06

COMBINATION THERAPY FOR TREATMENT OF CANCER

#1889
20250041310
2025-02-06

Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors

#1890
20250034756
2025-01-30

LIGAND-BINDING MOLECULE HAVING ADJUSTABLE LIGAND BINDING ACTIVITY

#1891
20250034279
2025-01-30

METHODS OF EFFECTING A HEMODYNAMIC CHANGE BY ADMINISTERING AN ANTI-NPR1 ANTIBODY

#1892
20250034278
2025-01-30

USE OF ALPHA-ENOLASE ANTAGONIST FOR TREATING ANGIOGENESIS-RELATED DISEASES

#1893
20250034277
2025-01-30

METHOD FOR PREVENTING AND/OR TREATING THROMBOEMBOLIC DISEASES

#1894
20250034276
2025-01-30

ANTI-GLYCAN ANTIBODIES AND USES THEREOF

#1895
20250034271
2025-01-30

ANTI-CD40 ANTIBODIES AND USES THEREOF

#1896
20250034270
2025-01-30

COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES

#1897
20250034266
2025-01-30

CCR8 ANTIGEN BINDING UNIT AND USES THEREOF

#1898
20250034265
2025-01-30

TREATMENT OF A DEMYELINATING DISEASE OF THE CENTRAL NERVOUS SYSTEM (CNS) WITH SATRALIZUMAB

#1899
20250034264
2025-01-30

REGULATING T CELL IMMUNE RESPONSE THROUGH IGF-I RECEPTOR (IGF-1R)

#1900
20250034263
2025-01-30

FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY

#1901
20250034260
2025-01-30

FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS

#1902
20250034259
2025-01-30

Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof

#1903
20250034256
2025-01-30

ANTI-PD-1 ANTIBODIES AND USES THEREOF

#1904
20250034254
2025-01-30

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY IN TREATING ESOPHAGEAL CANCER

#1905
20250034252
2025-01-30

MANABODIES TARGETING P53 TUMOR ANTIGENS AND METHODS OF USING

#1906
20250034248
2025-01-30

MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3

#1907
20250034242
2025-01-30

IL-21 POLYPEPTIDES AND TARGETED CONSTRUCTS

#1908
20250034239
2025-01-30

PROTEINS AND USE THEREOF

#1909
20250034235
2025-01-30

COMPOSITIONS FOR PREVENTING OR TREATING INFLUENZA INFECTIONS

#1910
20250032632
2025-01-30

DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF

#1911
20250032609
2025-01-30

USE OF SEMAPHORIN-4D ANTIBODIES IN COMBINATION WITH AN IMMUNE MODULATING THERAPY TO INHIBIT TUMOR GROWTH AND METASTASIS

#1912
20250032608
2025-01-30

TREATMENT OF ASTHMA WITH ANTI-TSL P ANTIBODY

#1913
20250032506
2025-01-30

GLUCOCORTICOID RECEPTOR BLOCKADE WITH MIFEPRISTONE TO SENSITIZE PANCREATIC CANCER TO IMMUNOTHERAPY

#1914
20250032495
2025-01-30

PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

#1915
20250032490
2025-01-30

THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

#1916
20250026858
2025-01-23

METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING LIGELIZUMAB

#1917
20250026857
2025-01-23

MINI BODIES AS VACCINES FOR HIV

#1918
20250026855
2025-01-23

ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF

#1919
20250026851
2025-01-23

ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR

#1920
20250026850
2025-01-23

ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES

#1921
20250026848
2025-01-23

IDENTIFICATION OF PATHOGENIC IMMUNE CELL SUBSETS IN CHECKPOINT INHIBITOR-INDUCED MYOCARDITIS

#1922
20250026847
2025-01-23

TREATMENT OF CD20-POSITIVE B-CELL LYMPHOMA WITH OBINUTUZUMAB

#1923
20250026843
2025-01-23

BISPECIFIC ANTIBODY AGAINST CD40 AND CLDN18.2 AND APPLICATION THEREOF

#1924
20250026835
2025-01-23

ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES

#1925
20250026834
2025-01-23

FELINE ANTIBODY VARIANTS

#1926
20250026833
2025-01-23

A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF

#1927
20250026832
2025-01-23

COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-1 INHIBITORS

#1928
20250026830
2025-01-23

Binding agents and methods of using the same

#1929
20250026827
2025-01-23

Anti-SIRP-Beta1 Antibodies and Methods of Use Thereof

#1930
20250026823
2025-01-23

BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS

#1931
20250026821
2025-01-23

ANTI-TGF-BETA ANTIBODIES AND THEIR USE

#1932
20250026819
2025-01-23

METHODS OF TREATMENT COMPRISING ANTIBODIES BINDING TO ALPHA7BETA1 INTEGRIN ANTIBODIES

#1933
20250026816
2025-01-23

Antibodies for Use as Therapeutics Against Bacterial Infections

#1934
20250026815
2025-01-23

ANTI-RSV ANTIBODY AND APPLICATION THEREOF

#1935
20250026814
2025-01-23

POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION

#1936
20250026803
2025-01-23

IMMUNOGLOBULINS AND USES THEREOF

#1937
20250025560
2025-01-23

METHOD FOR THE REVIVAL OF MICROGLIA AND ASTROCYTES AND APPLICATIONS THEREOF

#1938
20250025559
2025-01-23

IRF-4 ENGINEERED T CELLS AND USES THEREOF IN TREATING CANCER

#1939
20250019463
2025-01-16

METHOD FOR THE TREATMENT OF PROGRESSIVE CHRONIC INTERSTITIAL LUNG DISEASE

#1940
20250019462
2025-01-16

ANTIBODIES THAT SPECIFICALLY BIND TO API5 PROTEIN

#1941
20250019461
2025-01-16

HER3 ANTIGEN-BINDING MOLECULES

#1942
20250019456
2025-01-16

TARGETING IMMUNE INFILTRATION TO THE CENTRAL NERVOUS SYSTEM (CNS)

#1943
20250019454
2025-01-16

ANTI-TNFR2 ANTIBODIES AND USES THEREOF

#1944
20250019451
2025-01-16

ANTI-CCR8 ANTIBODIES AND USES THEREOF

#1945
20250019449
2025-01-16

ANTI-CCR8 AGENTS

#1946
20250019448
2025-01-16

SMO HUMAN ANTIBODY

#1947
20250019443
2025-01-16

ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF

#1948
20250019442
2025-01-16

BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF

#1949
20250019440
2025-01-16

IMMUNOMODULATORY TRISPECIFIC T CELL ENGAGER FUSION PROTEINS

#1950
20250019437
2025-01-16

ANTI-TREM2 ANTIBODY AND USES THEREOF

#1951
20250019436
2025-01-16

Bispecific Antibody against TIGIT and PD-L1, and Pharmaceutical Composition Thereof and Use Thereof

#1952
20250019435
2025-01-16

METHODS, COMPOSITIONS, AND KITS FOR MODIFYING IMMUNE CELL ACTIVITY VIA KIR2DL5

#1953
20250019433
2025-01-16

METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY

#1954
20250019430
2025-01-16

RESISTIN-SPECIFIC ANTIBODY AND USE THEREOF

#1955
20250019428
2025-01-16

Manufacturing Methods for Producing Anti-TNF Antibody Compositions

#1956
20250019427
2025-01-16

ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND USES THEREOF

#1957
20250019424
2025-01-16

VHH POLYPEPTIDES THAT BIND TO CLOSTRIDIUM DIFFICILE TOXIN B AND METHODS OF USE THEREOF

#1958
20250019413
2025-01-16

APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF

#1959
20250019412
2025-01-16

APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF

#1960
20250018053
2025-01-16

ANTI-NECTIN-4-ANTIBODIES AND USES THEREOF

#1961
20250018029
2025-01-16

METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY

#1962
20250018014
2025-01-16

METHOD FOR TREATING AND/OR PREVENTING REGNASE-1-RELATED DISEASE

#1963
20250017971
2025-01-16

TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS

#1964
20250011794
2025-01-09

TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME

#1965
20250011471
2025-01-09

ANTIBODIES AND METHODS OF USE

#1966
20250011470
2025-01-09

TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES

#1967
20250011469
2025-01-09

ANTI-CANCER PEPTIDE

#1968
20250011468
2025-01-09

Procoagulant Antibodies

#1969
20250011467
2025-01-09

ANTIBODIES THAT RECOGNIZE RED BLOOD CELL ANTIGENS

#1970
20250011466
2025-01-09

TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT

#1971
20250011462
2025-01-09

METHOD OF TREATING A TUMOR EXPRESSING CARBONIC ANHYDRASE IX (G250) BY ADMINISTERING A G250-SPECIFIC CHIMERIC ANTIGEN RECEPTOR

#1972
20250011461
2025-01-09

HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

#1973
20250011458
2025-01-09

Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies

#1974
20250011456
2025-01-09

ANTIBODIES AGAINST CD14 AND USES THEREOF

#1975
20250011455
2025-01-09

ANTI-CD39 Antibody, Preparation Method Therefor And Use Thereof

#1976
20250011448
2025-01-09

ANTIBODIES SPECIFICALLY RECOGNIZING TNFR2 AND USES THEREOF

#1977
20250011446
2025-01-09

ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES

#1978
20250011445
2025-01-09

COMBINATIONS OF ANTI-INFLAMMATORY AGENTS FOR TREATING ACUTE ORGAN FAILURE, ARDS, ORGANS FOR TRANSPLANTATION OR DISEASES CAUSED BY AN AIRWAY-TARGETING VIRUS

#1979
20250011441
2025-01-09

METHODS OF TREATING CHRONIC GRAFT-VERSUS-HOST DISEASE-RELATED BRONCHIOLITIS OBLITERANS SYNDROME USING AN ANTI-COLONY STIMULATING FACTOR 1 RECEPTOR ANTIBODY

#1980
20250011440
2025-01-09

Fc VARIANTS WITH ALTERED BINDING TO FcRn

#1981
20250011439
2025-01-09

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE OR CYSTEINE PROTEASE-CLEAVABLE SUBSTRATES AND METHODS OF USE THEREOF

#1982
20250011438
2025-01-09

Antibody Binding to Tie2 and Use Thereof

#1983
20250011436
2025-01-09

CLEC12a Binding Polypeptides and Uses Thereof

#1984
20250011435
2025-01-09

NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY

#1985
20250011433
2025-01-09

FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED COMPLEMENT BINDING

#1986
20250011431
2025-01-09

ANTI-CANINE PD-L1 ANTIBODIES

#1987
20250011430
2025-01-09

ANTI-B7H3 ANTIBODY AND USE THEREOF

#1988
20250011429
2025-01-09

Use of a Checkpoint Inhibitor in Combination with Ultralow Dose Whole Body Irradiation

#1989
20250011427
2025-01-09

ANTI-CD3 ANTIBODIES WITH CROSS-REACTIVITY TO HUMAN AND CYNOMOLGUS PROTEINS

#1990
20250011424
2025-01-09

ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF

#1991
20250011423
2025-01-09

METHODS TO REVERSE TREML1-INDUCED IMMUNE SUPPRESSION

#1992
20250011422
2025-01-09

SIGLEC-6 ANTIBODIES, DERIVATIVE COMPOUNDS AND RELATED USES

#1993
20250011421
2025-01-09

ANTIBODY AGAINST HUMAN TIGIT AND USE THEREOF

#1994
20250011418
2025-01-09

CANCER SPECIFIC PLECTIN-1 SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF

#1995
20250011417
2025-01-09

METHODS FOR THE TREATMENT OF THYROID EYE DISEASE

#1996
20250011416
2025-01-09

METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE

#1997
20250011415
2025-01-09

Safe and Effective Method of Treating Lupus with Anti-IL/IL23 Antibody

#1998
20250011414
2025-01-09

ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS

#1999
20250011413
2025-01-09

PRODUCTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA

#2000
20250011408
2025-01-09

METHODS AND COMPOSITIONS FOR REDUCING CENTRALIZED PAIN

#2001
20250011407
2025-01-09

METHODS OF USING ANTI-SCLEROSTIN ANTIBODIES IN TREATMENT OF OSTEOGENESIS IMPERFECTA

#2002
20250011406
2025-01-09

NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE

#2003
20250011405
2025-01-09

TREATMENT AND DIAGNOSIS OF DISEASES ASSOCIATED TO PATHOGENIC FIBROSIS

#2004
20250011402
2025-01-09

ANTIBODIES AGAINST DISEASE CAUSING AGENTS OF POULTRY AND USES THEREOF

#2005
20250011401
2025-01-09

OPTIMIZED NUCLEIC ACID ANTIBODY CONSTRUCTS

#2006
20250011398
2025-01-09

COMPOSTIONS

#2007
20250011397
2025-01-09

MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2

#2008
20250011375
2025-01-09

METHODS AND COMPOSITIONS FOR PREVENTING INFECTION

#2009
20250011340
2025-01-09

BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF

#2010
20250009876
2025-01-09

HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF

#2011
20250009772
2025-01-09

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

#2012
20250009677
2025-01-09

DENDRITIC CELL-MIMICKING FUNCTIONAL NANOSTRUCTURE COMPRISING CONTAINING aCTLA-4 AND METHOD FOR PRODUCING THE SAME

#2013
20250002610
2025-01-02

ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4

#2014
20250002607
2025-01-02

BISPECIFIC ANTIBODIES

#2015
20250002605
2025-01-02

BISPECIFIC ANTIBODY AND USE THEREOF

#2016
20250002603
2025-01-02

Humanized complement 5A receptor 1 antibodies and methods of use thereof

#2017
20250002601
2025-01-02

MULTISPECIFIC ANTIBODIES BINDING TO CD20, NKP46, CD16 AND CONJUGATED TO IL-2

#2018
20250002599
2025-01-02

BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGF-BETA AND USES THEREOF

#2019
20250002594
2025-01-02

ANTI-CD122 ANTIBODIES, ANTI-CD132 ANTIBODIES, AND RELATED BISPECIFIC BINDING PROTEINS

#2020
20250002591
2025-01-02

INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHERMATOSUS PATIENTS

#2021
20250002590
2025-01-02

TREATMENT OF LUPUS NEPHRITIS WITH ANTI-TYPE I INF RECEPTOR ANTIBODY ANIFROLUMAB

#2022
20250002589
2025-01-02

TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOUS

#2023
20250002588
2025-01-02

BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)

#2024
20250002587
2025-01-02

PREVENTION OF POSTERIOR CAPSULAR OPACIFICATION (PCO) WITH INTEGRIN AVB8 BLOCKING ANTIBODY

#2025
20250002585
2025-01-02

ACTIVATABLE BISPECIFIC ANTI-CD47 AND ANTI-PD-L1 PROTEINS AND USES THEREOF

#2026
20250002581
2025-01-02

HUMANIZED MONOCLONAL ANTIBODY FOR RESTORING DYSFUNCTIONAL HUMAN T AND B CELLS AGAINST CANCER AND VIRAL INFECTION

#2027
20250002580
2025-01-02

METHOD FOR INHIBITING CARDIAC FIBROBLAST TRANSDIFFERENTIATION

#2028
20250002574
2025-01-02

IL-11 HUMANIZED ANTIBODY AND APPLICATION THEREOF

#2029
20250002570
2025-01-02

ANTI-VEGF A AND VEGF C BISPECIFIC ANTIBODIES AND USE THEREOF

#2030
20250002569
2025-01-02

METHOD OF TREATING OSTEOARTHRITIS

#2031
20250002565
2025-01-02

HIV-BINDING PEPTIDES AND MEDICAL USE THEREOF

#2032
20250002553
2025-01-02

A GPC3-targeting antibody-interferon a fusion protein and a use thereof

#2033
20250000990
2025-01-02

COMBINATION THERAPIES FOR THE TREATMENT OF CANCER

#2034
20250000981
2025-01-02

METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY

#2035
20250000853
2025-01-02

COMBINATION OF A PD-1 ANTAGONIST AND A VEGF-R/FGFR/RET TYROSINE KINASE INHIBITOR FOR TREATING CANCER

#2036
20240425613
2024-12-26

PROTEIN S ANTIBODIES, METHODS OF MAKING AND USES THEREOF

#2037
20240425611
2024-12-26

Trispecific T cell Engagers

#2038
20240425609
2024-12-26

CD20-PD1 BINDING MOLECULES AND METHODS OF USE THEREOF

#2039
20240425608
2024-12-26

EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY

#2040
20240425607
2024-12-26

IL-18BP ANTAGONIST ANTIBODIES AND THEIR USE IN MONOTHERAPY AND COMBINATION THERAPY IN THE TREATMENT OF CANCER

#2041
20240425605
2024-12-26

TrkA ANTIBODY AND APPLICATION THEREOF

#2042
20240425603
2024-12-26

ANTI-VEGFR1 ANTIBODIES AND THEIR USES

#2043
20240425602
2024-12-26

COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH

#2044
20240425596
2024-12-26

COMPOSITIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF OBTAINING THE COMPOSITIONS THEREOF

#2045
20240425593
2024-12-26

ANTI-PD-1 ANTIBODY AND USE THEREOF

#2046
20240425591
2024-12-26

METHODS OF SUPPRESSING MICROGLIAL ACTIVATION

#2047
20240425589
2024-12-26

CYTOTOXICITY-INDUCING THERAPEUTIC AGENT FOR USE IN TREATMENT OF CANCER

#2048
20240425585
2024-12-26

ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

#2049
20240425584
2024-12-26

MECHANICALLY INTERLOCKING COMPLEXES

#2050
20240425581
2024-12-26

IL-7 Binding Proteins and Their Use in Medical Therapy

#2051
20240425580
2024-12-26

Anti-IL-33 Antibodies and Uses Thereof

#2052
20240425578
2024-12-26

IL-13 INHIBITORS FOR THE TREATMENT OF PRURIGO NODULARIS

#2053
20240425577
2024-12-26

PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA

#2054
20240425573
2024-12-26

METHODS FOR TREATING ALZHEIMER'S DISEASE

#2055
20240425569
2024-12-26

ANTIBODY MOLECULES TO DENGUE VIRUS AND USES THEREOF

#2056
20240425568
2024-12-26

COMBINATION THERAPIES FOR HIV INFECTIONS AND USES THEREOF

#2057
20240425561
2024-12-26

NEW INTERLEUKIN-7 IMMUNOCONJUGATES

#2058
20240425557
2024-12-26

Albumin Bound Macromolecule Tri-Agonist Activating GLP-1/GIP/Glucagon Receptors

#2059
20240424128
2024-12-26

HUMANIZED ANTIBODIES AGAINST NECTIN-2 AND DRUG CONJUGATES THEREOF

#2060
20240424124
2024-12-26

Immunoconjugates and methods

#2061
20240424123
2024-12-26

Immunoconjugates and methods

#2062
20240424122
2024-12-26

IMMUNOCONJUGATES AND METHODS

#2063
20240424121
2024-12-26

Immunoconjugates and methods

#2064
20240424091
2024-12-26

Methods for Inhibiting Fibrosis in a Subject in Need Thereof

#2065
20240424090
2024-12-26

COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY

#2066
20240424074
2024-12-26

ANTI-TUMOR DNA VACCINE WITH PD-1 AND LAG-3 PATHWAY BLOCKADE

#2067
20240424072
2024-12-26

Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor

#2068
20240424012
2024-12-26

COMBINATIONS AND USES THEREOF

#2069
20240423994
2024-12-26

TARGETING IMMUNE SUPPRESSION AFTER ATR INHIBITION

#2070
20240423927
2024-12-26

COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY

#2071
20240417812
2024-12-19

METHODS FOR TREATING SOLID CANCER PATIENTS WITH CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL

#2072
20240417483
2024-12-19

MONOCLONAL ANTIBODY AND A METHOD THEREOF

#2073
20240417482
2024-12-19

SINGLE-DOMAIN 4-1BB ANTIBODIES

#2074
20240417480
2024-12-19

COMPOSITION FOR TREATING IL-6-RELATED DISEASES

#2075
20240417478
2024-12-19

ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF

#2076
20240417477
2024-12-19

ANTIBODY CONJUGATES FOR THE TREATMENT OF CANCER

#2077
20240417475
2024-12-19

BISPECIFIC CD16A BINDERS

#2078
20240417472
2024-12-19

PD-1/TIM-3 BINDING PROTEINS FOR TREATMENT OF NSCLC and cHL

#2079
20240417471
2024-12-19

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

#2080
20240417469
2024-12-19

CD3-TARGETING T-CELL ENGAGERS WITH IMPROVED THERAPEUTIC INDEX

#2081
20240417466
2024-12-19

HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3

#2082
20240417464
2024-12-19

COMPOSITIONS COMPRISING ANTIGEN-BINDING MOLECULES

#2083
20240417463
2024-12-19

ANTI-CD47 ANTIBODIES AND METHODS OF USE THEREOF

#2084
20240417461
2024-12-19

NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

#2085
20240417460
2024-12-19

HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE

#2086
20240417456
2024-12-19

BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS

#2087
20240417455
2024-12-19

TREATMENT FOR RHEUMATOID ARTHRITIS

#2088
20240417451
2024-12-19

Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies

#2089
20240417450
2024-12-19

MONOCLONAL ANTIBODY-CONTAINING COMPOSITION FOR SUPPRESSING CLOSTRIDIUM DIFFICILE BACTERIA

#2090
20240417441
2024-12-19

POLYPEPTIDES, CELLS, AND METHODS INVOLVING ENGINEERED CD16

#2091
20240417433
2024-12-19

Bispecific Binding Molecule

#2092
20240415964
2024-12-19

NATURAL KILLER CELLS FOR CHORDOMA THERAPY

#2093
20240415959
2024-12-19

COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASE

#2094
20240415919
2024-12-19

COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCER

#2095
20240415917
2024-12-19

WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES

#2096
20240415906
2024-12-19

Combination Treatment

#2097
20240415888
2024-12-19

ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF

#2098
20240415841
2024-12-19

SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY

#2099
20240415828
2024-12-19

TLR7 AGONIST AND COMBINATIONS FOR CANCER TREATMENT

#2100
20240410009
2024-12-12

GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS